‘Hesitancy’ will be next snag with vaccinations

NEXT CHALLENGE: Panelists discuss the region’s rollout of the COVID-19 vaccine during the PBN Health Care Summit on April 8. Clockwise from top left is Dr. Karen Tashima, who directs clinical trials for Life­span Corp.; Dr. Kirsten Anderson, from Aetna/CVS Health; moderator PBN Editor Michael Mello; Dr. Ashish Jha, dean of the School of Public Health at Brown University; Christopher Palmieri, CEO and president of Commonwealth Care Alliance; and Peter Marino, CEO of Neighborhood Health Plan of Rhode Island.
NEXT CHALLENGE: Panelists discuss the region’s rollout of the COVID-19 vaccine during the PBN Health Care Summit on April 8. Clockwise from top left is Dr. Karen Tashima, who directs clinical trials for Life­span Corp.; Dr. Kirsten Anderson, from Aetna/CVS Health; moderator PBN Editor Michael Mello; Dr. Ashish Jha, dean of the School of Public Health at Brown University; Christopher Palmieri, CEO and president of Commonwealth Care Alliance; and Peter Marino, CEO of Neighborhood Health Plan of Rhode Island.
Rhode Island will soon hit a tipping point in COVID-19 vaccinations – a point at which there will be more vaccine available than the demand for it, according to public health professionals. And that’s not necessarily a positive development. So-called vaccine hesitancy, the term health officials use to describe reluctance or unwillingness to take a…

You must be a subscriber to read this content. To keep reading and receive unlimited access subscribe today for only $1.
Subscribe Now Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

No posts to display